• A. Abirami Department of pharmaceutics, K. M. College of pharmacy, Uthangudi, Madurai
  • S. Mohamed Halith Department of pharmaceutics, K. M. College of pharmacy, Uthangudi, Madurai
  • K. K. Pillai Department of pharmaceutics, K. M. College of pharmacy, Uthangudi, Madurai
  • Chithirra Anbalagan Department of pharmaceutics, K. M. College of pharmacy, Uthangudi, Madurai


Indomethacin, Pellet technology, Zero order kinetic model


Objective: The present investigation was to design pellets loaded with Indomethacin for extended release. Indomethacin is a non steroidal anti inflammatory drug (NSAID) commonly used for reduction of pain and inflammation. To improve the bioavailability indomethacin was prepared by fluidised bed coating tablet technology.

Methods: Indomethacin pellets were prepared using hydroxy propyl methyl cellulose and ethyl cellulose as a polymer in different concentration. Pellets were evaluated for physico - chemical properties such as hardness, friability, thickness, weight variation, drug content uniformity and capsule lock length. In vitro drug release studies were carried out USP rotating basket type I method and the samples were analyzed at 319nm by UV spectrophotometer.

Results: FT-IR studies revealed that there was no interaction betweeen drug and polymers used in the study. The drug release from F5 formulation was found to zero order kinetic model. It was also found linear in higuchi plot which confirms that diffusion is one of the mechanism of drug release.

Conclusion: Among these formulations, Formulation (F5) containing Ethyl cellulose (4cps) 5mg & HPC 20 mg and extended release coating upto 7% showed optimized release pattern.The optimized formulation (F5) releases the drug upto 24hrs and fulfilled the requirements such as cost effective and high patient compliance.


Download data is not yet available.


Sweetman SC, Blake PS. Martindale:the complete drug reference. Vol 1. Pharmaceutical Press, London:2007,35 ed,58-110.

Prichard PJ, Poniatowska TJ, Willars JE, Ravenscroft AT, Hawkey CJ. Effect in man of aspirin, standard indomethacin, and sustained release indomethacin preparations on gastric bleeding. Br J Clin Pharmacol 1988;26:167-72.

Sturges HF, Krone CL. Ulceration and stricture of the jejunum in a patient on long-termindomethacin therapy. Am J Gastroenterol 1973;59:162-9.

Tang Elaine SK, Chan LW, Heng Paul WS. Coating of multiparticulates for sustained release. Am J Drug Deliv 2005;3:17-328.

Li SP, Feld KM, Kowarski CR. Preparation of a controlled release drug delivery system of Indomethacin. J Drug Dev Ind Pharm 1994;20:1121-45.

Dempski RE, Mehta GN, Saboe JC, inventors;merck and Co Inc. Sustained release indomethacin. J United State patent 4173626. 1979, Nov 6.

Suryakusuma H, Jun HW. Encapsulated hydrophilic polymer beads containing indomethacin as controlled release drug delivery systems. J Pharm Pharmacol 1984;36:497-501.

Pong paibul Y, Price JC, Withworth CW. Preparation and evaluation of controlled release Indomethacin microspheres. J Drug Dev Ind Pharm 1984;10:1597-1609.

Hopfgartner J, Hurka W, Grablowitz O, W, inventors;Arcana, Chem Pharm Fabrik. Process of producing a sustained release preparation containing indomethacin or niomethacin. J United State patent 4652442. 1987, Mar 24.

Ghebre-Sellassie I, editor. Pharmaceutical pelletization Technology. J New York Marcel Dekker;1989.

Laicher A, lorck CA, Tobin J, Stanislaus F. Process optimization of pellet coating and drying using fluid bed production units. J Pharm Tech Eur 1994;8:41-8.

USP Drug Information for the Health Care Professionals. Thomson Micromedex Inc., Greenwood village:25 th ed, 2005.



How to Cite

Abirami, A., S. M. Halith, K. K. Pillai, and C. Anbalagan. “FORMULATION AND EVALUATION OF INDOMETHACIN EXTENDED RELEASE PELLETS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 7, July 2014, pp. 247-50,



Original Article(s)